Navigation Links
Nektar Presents Target-Specific Biomarkers Being Assessed in Ongoing Phase 3 BEACON Study of Etirinotecan Pegol for the Treatment of Metastatic Breast Cancer at the 2013 American Society of Clinical Oncology Annual Meeting
Date:6/1/2013

CHICAGO and SAN FRANCISCO, June 1, 2013 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) announced today that it presented a series of target-specific biomarkers that are being evaluated in the development of etirinotecan pegol for the treatment of breast cancer.  Etirinotecan pegol is a unique, next generation, targeted topoisomerase I inhibitor currently in Phase 3 clinical development as a potential treatment for patients with locally recurrent or metastatic breast cancer.  The BEACON (BrEAst Cancer Outcomes with NKTR-102) Phase 3 Study is a randomized, open-label, international study that is evaluating single agent etirinotecan pegol in patients who have previously received an anthracycline, a taxane and capecitabine (ATC) versus a comparator arm consisting of an active single agent treatment of physician's choice (TPC).

"One of our objectives in treating metastatic breast cancer is to prospectively identify patients that will respond to specific treatments so they can achieve the optimal individualized care," said Hope Rugo , M.D., Director of Breast Oncology and Clinical Trials Education at the UCSF Helen Diller Comprehensive Cancer Center and Member of the BEACON Study investigator steering committee. "The goal of evaluating these important biomarkers in patients enrolled into the BEACON study is to help us understand which breast cancer patients might have the best clinical outcomes from treatment with etirinotecan pegol."

A series of assays for target-specific pharmacodynamic biomarkers for etirinotecan pegol, including the molecular target topoisomerase I, have been established and are being measured in the Phase 3 BEACON study.  The biomarkers were identified from Circulating Tumor Cell (CTC) samples which were collected prior to patient treatment.&#
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Nektar to Announce Financial Results for the First Quarter of 2012 on Wednesday, May 2, 2012, After Close of U.S.-Based Financial Markets
2. Nektar Therapeutics Reports Financial Results for the First Quarter of 2012
3. Nektar Therapeutics President and CEO Howard W. Robin to Present at the Jefferies 2012 Global Healthcare Conference in New York
4. Nektar Announces that FDA Grants Fast Track Designation to NKTR-181, a New Oral Opioid Analgesic Molecule, for the Treatment of Moderate to Severe Chronic Pain
5. Nektar Announces Start of Enrollment in Phase 2 Study of NKTR-181, a Novel Opioid Analgesic Molecule, for Treatment of Chronic Pain
6. Nektar Announces Initiation of Investigator-Sponsored Trial Evaluating Etirinotecan Pegol (NKTR-102) in Patients with Bevacizumab (Avastin)-resistant High-Grade Glioma
7. Nektar Therapeutics Reports Financial Results for the Second Quarter of 2012
8. Nektar Therapeutics President and CEO, Howard W. Robin, To Present at the UBS 2012 Global Life Sciences Conference in New York City
9. Nektar to Announce Financial Results for the Third Quarter of 2012 On Tuesday, November 13, 2012, After Close of U.S.-Based Financial Markets
10. Nektar Announces that FDA Grants Fast Track Designation to Etirinotecan Pegol (NKTR-102) for the Treatment of Metastatic Breast Cancer
11. Nektar To Host Conference Call To Discuss The Positive Phase 3 Clinical Results For Naloxegol
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... , Aug. 3, 2015  BioElectronics Corporation (OTC Pink: ... management, announced that Andrew J. Whelan , President ... his program "On Business" at 9am EDT on Wednesday, ... live, tune to: http://tunein.com/radio/Money-Matters-Boston-1120-s27548/ ... the exceptional acceptance the company,s flagship product, ActiPatch Therapy, ...
(Date:8/3/2015)... , Aug. 3, 2015  Charleston Laboratories, Inc., ... its second clinical development program with a Phase ... CL-H1T contains fast-dissolving promethazine and ... as a treatment for migraine headache pain and ... "Many patients with migraine headaches also suffer from ...
(Date:8/3/2015)... -- Encision Inc. (PK:ECIA), a medical device company owning patented ... minimally invasive surgery, today announced financial results for its ... The Company posted quarterly net revenue of ... thousand, or $(0.02) per share. These results compare to ... of $202 thousand, or $(0.02) per share, in the ...
Breaking Medicine Technology:UpTick News Wire Radio Show Will Interview BioElectronics' CEO Andrew Whelan 2Charleston Laboratories, Inc. Initiates Patient Enrollment in a Phase 1 Study of Charleston's Second Product, CL-H1T 2Encision Reports First Quarter Fiscal Year 2016 Results 2Encision Reports First Quarter Fiscal Year 2016 Results 3Encision Reports First Quarter Fiscal Year 2016 Results 4Encision Reports First Quarter Fiscal Year 2016 Results 5
... (Nasdaq: PRGO ; TASE) today announced that ... calcipotriene 0.005% and betamethasone dipropionate 0.064% ointment, a generic ... first to file on this product. Taclonex® ... treatment of psoriasis vulgaris in adults 18 years of ...
... NEW YORK, Feb. 22, 2011 Reportlinker.com announces ... in its catalogue: Global Pharmaceutical ... This report analyzes the worldwide ... by the following Dosage Forms: Injectables (Injections, Vials, ...
Cached Medicine Technology:Perrigo Confirms Filing for Generic Version of Taclonex® Ointment and Announcement of Lawsuit by Leo Pharma 2Perrigo Confirms Filing for Generic Version of Taclonex® Ointment and Announcement of Lawsuit by Leo Pharma 3Reportlinker Adds Global Pharmaceutical Contract Manufacturing Industry 2
(Date:8/3/2015)... (PRWEB) , ... August 03, 2015 , ... ... announce the development of it’s new program “Designing Secure Healthcare Systems” This ... engineers and technology leaders from healthcare organizations with access to the tactics, techniques ...
(Date:8/3/2015)... CA (PRWEB) , ... August 03, 2015 , ... A ... emerged among U.S. emergency rooms in recent years, according to the American Dental Association. ... number of dental emergency visits went from 1.1 million in a single year to ...
(Date:8/3/2015)... (PRWEB) , ... August 03, 2015 , ... Illinois Health ... effective July 31. , The acquisition includes all of IBAM NA’s cyclotron sites ... to have both, a robust regionally located business, as well as a large manufacturing ...
(Date:8/3/2015)... (PRWEB) , ... August 03, 2015 , ... Constantin Vasilica, ... accompanied by tissue injury caused by diabetes after many years of suffering and using ... times, and he didn’t want to ask for extra time off or wait longer ...
(Date:8/3/2015)... ... August 03, 2015 , ... ... medical information, risk management and investigative services, has introduced a new logo ... expert information solutions that improve business outcomes for its customers. EMSI’s new ...
Breaking Medicine News(10 mins):Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 2Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 3Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 4Health News:Los Angeles Periodontists Comment on Rising Dental Emergency Room Trips 2Health News:Los Angeles Periodontists Comment on Rising Dental Emergency Room Trips 3Health News:Illinois Health & Science Expands Nuclear Medicine Footprint With Purchase of IBA Molecular North America, Inc. 2Health News:Chinese Health Care Provider Heshoutang Now Give Patients Complimentary Online Healing Options 2Health News:Chinese Health Care Provider Heshoutang Now Give Patients Complimentary Online Healing Options 3Health News:EMSI Announces New Branding: Powerful Information. Improved Outcomes. 2
... Partnerships at The Henry M. Jackson Foundation for the ... the recipients of the 2012 Heroes of Military Medicine ... selfless dedication to advancing medicine for our nation,s wounded, ... The recipients will be honored at the Heroes of ...
... Washington, D.C. People with schizophrenia report ... clinical program, according to results announced today from ... of Care for People with Schizophrenia , was ... Healthcare (National Council) and administered at 10 community ...
... TUESDAY, March 6 (HealthDay News) -- ,Hospitalizations from angiodema, ... skin often around the eyes and mouth, are on ... York Downtown Hospital searched a national database for hospitalizations ... fatal whole-body reaction) and angiodema. While hospitalization rates ...
... The American College of Physicians (ACP) today issued a ... is the second leading cause of cancer-related deaths for ... statement and a patient summary appear in the March ... published by ACP. ACP developed this guidance statement ...
... , MONDAY, March 5 (HealthDay News) -- Pregnant women taking ... reduced head growth, a new study suggests. The researchers ... as Paxil and Prozac relieved depression in these women, they ... birth. "Fetal body growth is a marker of fetal ...
... Jenifer Goodwin HealthDay Reporter , MONDAY, March ... or have other breathing issues while sleeping are more ... 7, new research suggests. Those issues can include ... depression, conduct problems such as rule-breaking and aggressiveness and ...
Cached Medicine News:Health News:HJF Center announces Heroes of Military Medicine award recipients 2Health News:Pilot program demonstrates measureable benefits for people with schizophrenia 2Health News:American College of Physicians releases new colorectal cancer screening guidance statement 2Health News:Moms' Antidepressants May Affect Babies' Head Size: Study 2Health News:Moms' Antidepressants May Affect Babies' Head Size: Study 3Health News:Snoring Tots May Develop Behavioral Issues Later 2Health News:Snoring Tots May Develop Behavioral Issues Later 3
... Plus Dodeca cell accommodates up to 12 ... first-dimension runs in the PROTEAN IEF system, ... format. The PROTEAN Plus Dodeca cell's cooling ... electrodes, allow consistent, high-resolution results. The handcasting ...
... The PROTEAN Plus Dodeca cell accommodates up ... capacity of first-dimension runs in the PROTEAN ... a convenient format. The PROTEAN Plus Dodeca ... its plate electrodes, allow consistent, high-resolution results. ...
... gels run in the specially designed E-Base™ ... power supply in one device. The daughter ... and to other daughter E-Base™ platforms for ... E-Gel® 96 or E-Gel® 48 gels. Note: ...
... E-Gel® 48 gels run in the ... combine the base and power supply ... E-Base™ power supply contains an electrical ... to an electrical outlet and is ...
Medicine Products: